{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/VNDA/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T01:26:29.873Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3480,"canonical_name":"Vanda Pharmaceuticals Inc.","cik":"0001347178","uei":null,"lei":null,"duns":null,"ticker":"VNDA"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":21,"clinical":4,"open":1},"count":26,"timeline":[{"ts":"2026-06-08","kind":"sec.filing","form_type":"3","title":"3 — Vanda Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001347178/3/0001193125-26-261752","accession_number":"0001193125-26-261752","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Vanda Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001347178/4/0001193125-26-261790","accession_number":"0001193125-26-261790","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Vanda Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001347178/4/0001193125-26-261806","accession_number":"0001193125-26-261806","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Vanda Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001347178/4/0001193125-26-261811","accession_number":"0001193125-26-261811","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Vanda Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001347178/4/0001193125-26-261871","accession_number":"0001193125-26-261871","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Vanda Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001347178/4/0001193125-26-261768","accession_number":"0001193125-26-261768","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"4","title":"4 — Vanda Pharmaceuticals Inc. — 2026-06-08","url_slug":"/sec/cik-0001347178/4/0001193125-26-261782","accession_number":"0001193125-26-261782","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"8-K","title":"8-K — Vanda Pharmaceuticals Inc. — 2026-06-05","url_slug":"/sec/cik-0001347178/8-k/0001628280-26-041298","accession_number":"0001628280-26-041298","importance":35},{"ts":"2026-06-05","kind":"sec.filing","form_type":"S-8","title":"S-8 — Vanda Pharmaceuticals Inc. — 2026-06-05","url_slug":"/sec/cik-0001347178/s-8/0001628280-26-041303","accession_number":"0001628280-26-041303","importance":30},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"DUGAN RICHARD W","title":null,"shares":41600,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Ward Anne Sempowski","title":null,"shares":41600,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Duncan Charles Cliff","title":null,"shares":41600,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Chrousos Phaedra","title":null,"shares":41600,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"McGuire Daniel Patrick","title":"SVP, GC and Secretary","shares":80000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Mitchell Stephen Ray","title":null,"shares":41600,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Honore Tage","title":null,"shares":41600,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Vanda Pharmaceuticals Inc. — 2026-05-20","url_slug":"/sec/cik-0001347178/4/0001802653-26-000003","accession_number":"0001802653-26-000003","importance":30},{"ts":"2026-05-18","kind":"sec.insider.g","reporter":"Mitchell Stephen Ray","title":null,"shares":25836,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-12","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Vanda Pharmaceuticals Inc. — 2026-05-12","url_slug":"/sec/cik-0001347178/schedule-13g/0000093751-26-000309","accession_number":"0000093751-26-000309","importance":55},{"ts":"2026-05-12","kind":"sec.13dg","reporter":"Vanda Pharmaceuticals Inc.","shares":3015562,"percent_of_class":5.1,"security_title":"SCHEDULE 13G","accession_number":"0000093751-26-000309","excerpt":null,"importance":55},{"ts":"2026-04-24","kind":"sec.filing","form_type":"CORRESP","title":"CORRESP — Vanda Pharmaceuticals Inc. — 2026-04-24","url_slug":"/sec/cik-0001347178/corresp/0001193125-26-177526","accession_number":"0001193125-26-177526","importance":30},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"Vanda Pharmaceuticals","title":"A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07446439","excerpt":"[\"Nausea and Vomiting\",\"Obesity\"]","importance":60},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Vanda Pharmaceuticals","title":"Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06138613","excerpt":"[\"Motion Sickness\"]","importance":60},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Vanda Pharmaceuticals","title":"Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07221578","excerpt":"[\"Social Anxiety Disorder (SAD)\"]","importance":60},{"ts":"2026-03-27","kind":"clinical.trial","reporter":"Vanda Pharmaceuticals","title":"Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP","security_title":"PHASE3","status":"TERMINATED","accession_number":"NCT05366855","excerpt":"AnaptysBio has concluded the GEMINI-2 trial, with all trial participants having been treated with imsidolimab for approximately six months and the furthest subject having been treated through 104 weeks.","importance":80},{"ts":"2024-12-31","kind":"open.payments","reporter":"Vanda Pharmaceuticals Inc.","title":"$4532963.0 to 13380 physicians (2024–2024)","security_title":"manufacturer","excerpt":"FANAPT","accession_number":"2024","usd_value":4532963,"importance":70}]}